Ivax To Launch Neurontin Generics Early Under Settlement With Alpharma
This article was originally published in The Pink Sheet Daily
Executive Summary
The company's AB-rated generics of Neurontin capsules can come to market two weeks before Alpharma's 180-day exclusivity period runs out; Ivax' gabapentin tablets will be able to enter the market six weeks early. The settlement ends Ivax' challenge of FDA's patent-based award of generic exclusivity for Pfizer's epilepsy agent.